Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
HCG (Human Chorionic Gonadotropin) vs Tamoxifen (Nolvadex): they're closely matched on evidence (5.5 vs 5.2/10); they're alternatives for fertility support — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
HCG (Human Chorionic Gonadotropin) and Tamoxifen (Nolvadex) are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both HCG (Human Chorionic Gonadotropin) and Tamoxifen (Nolvadex) have evidence — compare verdict strength side-by-side.
Prescription-only and indication-dependent. For intratesticular-testosterone maintenance on TRT, the cited studies used 125-500 IU every other day (intramuscular in the one that states the route). For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No cited study gives these two doses. No dietary-supplement dose exists.
Any time of day
Prescription hCG — recombinant (choriogonadotropin alfa) or urinary-derived, by injection
Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.
Any time of day
Tamoxifen citrate tablets (approved for breast cancer; off-label in men)
and 1 more not shown
Weeks
Months
Months
Within ~36 hours
Years
Weeks to months
Weeks to a few months
Throughout use
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
J Clin Endocrinol Metab (2005) · Rct · n=29
29 men with normal reproductive physiology randomized to weekly testosterone enanthate plus saline placebo or 125, 250, or 500 IU hCG every other day for 3 weeks
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
J Urol (2013) · Observational · n=26
Retrospective cohort of 26 hypogonadal men on testosterone replacement plus 500 IU intramuscular hCG every other day, mean follow-up 6.2 months
A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.
Fertil Steril (2009) · Observational · n=100
Combined analysis of four Phase III open-label studies in 100 men with complete idiopathic or acquired hypogonadotropic hypogonadism, pretreated with hCG for 3-6 months then hCG plus recombinant FSH
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet (2011) · Meta analysis
EBCTCG patient-level meta-analysis of randomized adjuvant-tamoxifen trials; ER-positive disease cohort n=10,645
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst (1998) · Rct · n=13388
NSABP P-1: randomized, placebo-controlled prevention trial of 20 mg/day tamoxifen for 5 years in 13,388 women at increased breast-cancer risk
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Clin Genitourin Cancer (2012) · Rct · n=176
Randomized multicenter trial in 176 men on bicalutamide monotherapy for prostate cancer: reactive tamoxifen 20 mg/day (arm A) vs prophylactic tamoxifen 10 mg/day started with bicalutamide (arm B)
Both HCG (Human Chorionic Gonadotropin) and Tamoxifen (Nolvadex) are closely matched — the best choice depends on your specific health goals.
For fertility support, HCG (Human Chorionic Gonadotropin) has a higher relevance score (62 vs 42).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.